CSL Seqirus has announced that its nine-valent human papillomavirus vaccine, GARDASIL9, is now registered for use in males aged 9 to 45.
CSL Seqirus secures expanded approval for nine-valent HPV vaccine
September 15, 2023 Latest NewsBioPharma
Latest Video
New Stories
-
NDIS keeps growing but signs emerge that reforms are starting to work
July 17, 2025 - - Latest News -
USTR launches new investigation, with minimal ambition on pharmaceuticals
July 17, 2025 - - Latest News -
New Zealand starting to benefit after lifting advertising prohibition
July 17, 2025 - - Latest News -
Mark Butler restates support for health technology assessment reform
July 16, 2025 - - Latest News -
Brandon BioCatalyst welcomes the inclusion of its CUREator in new program
July 16, 2025 - - Australian Biotech -
Cancer Australia launches research program targeting early-onset cancers
July 16, 2025 - - Latest News -
Imugene completes significant placement and launches share purchase plan
July 16, 2025 - - Australian Biotech